Lanifibranor is an indole sulfonamide derivative and a balanced pan-PPAR agonist that has demonstrated strong therapeutic potential in pre-clinical models of NAFLD/NASH [156]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.